Minmin Wang

Minmin Wang

Auto-generated profile, based on publicly available information

Minmin Wang

China Center for Health Development Studies, Peking University, Beijing, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in JCO Global Oncology
Verified
Journal Article
Closed access
MWMinmin Wang
Minmin Wang
YBYanxin Bi
Yanxin Bi
YJYINZI JIN
YINZI JIN
ZHIJIE ZHENGZHIJIE ZHENG
ZHIJIE ZHENG
PURPOSE: Ovarian cancer can be categorized into distinct histologic subtypes with varying identifiable risk factors, molecular composition, clinical features, and treatment. The global incidence of ovarian cancer subtypes remains limited, especially in low- and middle-income countries (LMICs) without high-quality cancer registry systems. MATERIALS AND METHODS: We used data from population-based cancer registries of the Cancer Incidence in Five Continents project to calculate the proportions of serous, mucinous, endometrioid, clear cell, and other histologic subtypes of ovarian cancer. Proportions were applied to the estimated numbers of patients with ovarian cancer from Global Cancer Observatory 2020. Age-standardized incidence rates were calculated. RESULTS: Globally, an estimated 133,818 new patients of serous cancer, 35,712 new patients of mucinous cancer, 29,319 new patients of endometrioid cancer, and 17,894 new patients of clear cell cancer were identified in 2020. The distribution of ovarian cancer histologic subtypes exhibited regional variation. Eastern Europe had the highest rate of serous and mucinous carcinomas, whereas Northern Africa and Eastern Asia had the highest burden of endometrioid and clear cell carcinomas, respectively. CONCLUSION: This study provides a global incidence landscape of histologic subtypes of ovarian cancer, particularly in LMICs lacking comprehensive registry systems. Our analysis offers valuable insights into disease burden and guidance for tailored strategies for prevention of ovarian cancer.

25 August 2023 in Journal of Global Health
Verified
Journal Article
Open access
MWMinmin Wang
Minmin Wang
YJYINZI JIN
YINZI JIN
ZHIJIE ZHENGZHIJIE ZHENG
ZHIJIE ZHENG
Cervical cancer is the second most common cancer and the second most common cause of death from cancer in women of reproductive age worldwide [1]. In developing countries, cervical cancer ranks the second most common and lethal tumours, while it ranks the tenth in developed countries [2], making cervical cancer an example of global inequality […]

27 November 2023 in Journal of Diabetes
Verified
Journal Article
Open access
MWMinmin Wang
Minmin Wang
JLJingyi Liu
Jingyi Liu
JWJia Wang
Jia Wang
YJYINZI JIN
YINZI JIN
ZZZhi‐Jie Zheng
Zhi‐Jie Zheng
Background: Tracheal, bronchus, and lung (TBL) cancer is the third most common and lethal type of cancer worldwide. Glucose metabolism disorders, as represented by high fasting plasma glucose (HFPG), increase the risk of development and worsen the prognosis of TBL cancer. This study aimed to evaluate the global disease burden of TBL cancer attributable to HFPG.Methods: The TBL cancer burden attributable to HFPG was estimated based on a modeling strategy using the Global Burden of Disease Study 2019. The disease burden globally and by regions, countries, development levels, age groups, and sexes were also evaluated with the indicators of death, disability‐adjusted life years, years of life lost, and years lived with disability. The estimated annual percentage change (EAPC) was calculated by regression model to show the temporal trend.Results: In 2019, approximately 8% of the total TBL cancer burden was attributable to HFPG. The HFPG‐attributable TBL cancer burden increased globally from 1990 to 2019 with the EAPC of 0.98% per year. The burden was positively associated with social development levels, and the global burden was three times greater in men than in women. HFPG‐attributable TBL cancer burden increased with age and peaked at above 70 years of age.Conclusions: The findings highlight the effect and burden of glucose disorders, as represented by HFPG on TBL cancer burden. Integrated cancer prevention and control measures are needed, with control of glucose disorders as one of the key elements. image

25 October 2024 in Journal of Global Health
Verified
Journal Article
Open access
MWMinmin Wang
Minmin Wang
HCHongda Chen
Hongda Chen
Martin WongMartin Wong
Martin Wong
Junjie HuangJunjie Huang
Junjie Huang
YJYINZI JIN
YINZI JIN
ZHIJIE ZHENGZHIJIE ZHENG
ZHIJIE ZHENG
Cervical cancer is one of the gravest threats to women’s lives worldwide and also contributes to the socioeconomic inequality in disease burden [1]. In 2020, around 90% of the 604 127 incident cases and 341 831 deaths due to cervical cancer were estimated in low and middle-income countries (LMIC) [2]. Vaccination against human papilloma virus and screening […]

22 March 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
YBYanxin Bi
Yanxin Bi
KHKepei Huang
Kepei Huang
MWMinmin Wang
Minmin Wang
YJYINZI JIN
YINZI JIN
ZZZhi-Jie Zheng
Zhi-Jie Zheng
Objectives This study aimed to evaluate the global, regional and national disparities in the quality of care for leukaemia and brain and central nervous system (CNS) tumours among children and adolescents aged 0–19 years. We also assessed temporal trends in the quality of care index (QCI) and explored associations with sociodemographic development levels, gender and age. Setting The study used data from the Global Burden of Disease (GBD) 2019 database, covering 204 countries and territories. The analysis included global, regional and national levels of care, stratified by sociodemographic index (SDI), gender and age groups. Participants The study included children and adolescents aged 0–19 years diagnosed with leukaemia or CNS tumours. Data on incidence, prevalence, mortality and disability-adjusted life years (DALYs) were extracted from the GBD 2019 database. Primary and secondary outcome measures The primary outcome was the QCI, constructed using principal component analysis from four secondary indicators: years of life lost to years lived with disability ratio, DALYs to prevalence ratio, mortality to incidence ratio and prevalence to incidence ratio. Secondary outcomes included temporal trends in QCI, gender disparity ratios (GDRs) and correlations between QCI and SDI levels. Results In 2019, leukaemia and CNS tumours accounted for 132 194 deaths globally. The QCI for leukaemia was 74.71, while for CNS tumours, it was 56.59. From 1990 to 2019, the QCI for CNS tumours increased significantly (estimated annual percentage change (EAPC)=1.45, 95% CI: 1.41 to 1.50), whereas the QCI for leukaemia showed a declining trend in middle and low-middle SDI regions (EAPC=−0.13, 95% CI: −0.16 to –0.09). Western Europe had the highest QCI for leukaemia (94.50), while South Asia had the lowest (57.64). Boys had lower QCI scores than girls, and the gender disparity in CNS tumours widened over time (GDR increased from 1.147 in 1990 to 1.160 in 2019). QCI was positively correlated with SDI levels (leukaemia: r=0.591, p<0.001; CNS tumours: r=0.812, p<0.001). Conclusions This study highlights significant disparities in the quality of childhood cancer care across regions, development levels and genders. While global QCI for CNS tumours improved, leukaemia care quality declined in middle and low-middle SDI regions. Boys and populations in low SDI regions are particularly vulnerable to poor care. Policymakers should prioritise targeted interventions to address these disparities, improve access to quality care and reduce the global burden of childhood cancer.

7 June 2022 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
HYHanzhi Yu
Hanzhi Yu
RDRunming Du
Runming Du
MWMinmin Wang
Minmin Wang
FYFengyun Yu
Fengyun Yu
TYTao Jun Yang
Tao Jun Yang
SCSimiao Chen
Simiao Chen
Background: COVID-19 vaccines are in short supply worldwide. China was among the first countries to pledge supplies of the COVID-19 vaccine as a global public product, and to date, the country has provided more than 600 million vaccines to more than 200 countries and regions with low COVID-19 vaccination rates. Understanding the public’s attitude in China toward the global distribution of COVID-19 vaccines could inform global and national decisions, policies, and debates. Objective: The aim of this study was to determine the attitudes of adults living in China regarding the global allocation of COVID-19 vaccines developed in China and how these attitudes vary across provinces and by sociodemographic characteristics. Methods: We conducted a cross-sectional online survey among adults registered with the survey company KuRunData. The survey asked participants 31 questions about their attitudes regarding the global allocation of COVID-19 vaccines developed in China. We disaggregated responses by province and sociodemographic characteristics. All analyses used survey sampling weights. Results: A total of 10,000 participants completed the questionnaire. Participants generally favored providing COVID-19 vaccines to foreign countries before fulfilling domestic needs (75.6%, 95% CI 74.6%-76.5%). Women (3778/4921, 76.8%; odds ratio 1.18, 95% CI 1.07-1.32; P=.002) and those living in rural areas (3123/4065, 76.8%; odds ratio 1.13, 95% CI 1.01-1.27; P=.03) were especially likely to hold this opinion. Most respondents preferred providing financial support through international platforms rather than directly offering support to individual countries (72.1%, 95% CI 71%-73.1%), while for vaccine products they preferred direct provision to relevant countries instead of via a delivery platform such as COVAX (77.3%, 95% CI 76.3%-78.2%). Conclusions: Among our survey sample, we found that adults are generally supportive of the international distribution of COVID-19 vaccines, which may encourage policy makers to support and implement the distribution of COVID-19 vaccines developed in China worldwide. Conducting similar surveys in other countries could help align policy makers’ actions on COVID-19 vaccine distribution with the preferences of their constituencies.